Amgen (AMGN) Change in Accured Expenses (2009 - 2026)

Amgen has reported Change in Accured Expenses for 18 years, with the latest figure at $852.0 million in Q2 2026.

• On a quarterly basis, Change in Accured Expenses rose 5.97% year-over-year to $852.0 million in Q2 2026; TTM through Jun 2026 was $462.0 million, a 20.63% increase from a year earlier, with the FY2025 full-year figure at $499.0 million, up 442.39% from the prior year.
• Change in Accured Expenses was $852.0 million for Q2 2026 at Amgen, up from -$959.0 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $1.1 billion in Q4 2023, with the low at -$1.1 billion in Q1 2024.
• Average Change in Accured Expenses over 5 years is $69.7 million, with a median of $119.5 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses soared 323.23% in 2022, then tumbled 358.26% in 2024.
• Over 5 years, Change in Accured Expenses stood at -$645.0 million in 2022, then jumped by 271.01% to $1.1 billion in 2023, then tumbled by 34.0% to $728.0 million in 2024, then grew by 2.88% to $749.0 million in 2025, then climbed by 13.75% to $852.0 million in 2026.
• The last three Change in Accured Expenses figures came in at $852.0 million (Q2 2026), -$959.0 million (Q1 2026), and $749.0 million (Q4 2025), per Business Quant data.